CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

NCT02794961 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Recurrent or Refractory B Cell Malignancy

Interventions

BIOLOGICAL: CD22 CAR-T

Sponsor

Kai Lin Xu; Jun Nian Zheng

Collaborators

[object Object]